bioAffinity Technologies (BIAF) to Release Quarterly Earnings on Monday

bioAffinity Technologies (NASDAQ:BIAF) is anticipated to release its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect bioAffinity Technologies to post earnings of ($2.70) per share and revenue of $1.5530 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 12:30 PM ET.

bioAffinity Technologies (NASDAQ:BIAF) last issued its quarterly earnings results on Saturday, March 14th. The company reported ($1.11) EPS for the quarter, beating analysts’ consensus estimates of ($2.70) by $1.59. bioAffinity Technologies had a negative net margin of 241.93% and a negative return on equity of 301.67%. The business had revenue of $1.59 million for the quarter, compared to analysts’ expectations of $1.55 million.

bioAffinity Technologies Stock Performance

Shares of bioAffinity Technologies stock opened at $4.00 on Friday. The business has a 50-day moving average price of $1.59 and a two-hundred day moving average price of $2.21. bioAffinity Technologies has a 1-year low of $0.69 and a 1-year high of $46.53. The company has a current ratio of 2.60, a quick ratio of 2.58 and a debt-to-equity ratio of 0.08. The company has a market cap of $18 million, a P/E ratio of -0.25 and a beta of 2.42.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of bioAffinity Technologies in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Reduce”.

Institutional Investors Weigh In On bioAffinity Technologies

An institutional investor recently bought a new position in bioAffinity Technologies stock. Geode Capital Management LLC acquired a new stake in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,422 shares of the company’s stock, valued at approximately $36,000. Geode Capital Management LLC owned 0.68% of bioAffinity Technologies at the end of the most recent quarter. 1.64% of the stock is owned by institutional investors and hedge funds.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.